GLP-1 agonist drugs like Ozempic, and SLGT2 inhibitor drugs like Jardiance have been linked with a lower risk of a second ...
Now, it's up to the European Commission to confirm those potential green lights in the coming weeks and months.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback